Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial
Abstract Alzheimer’s disease (AD) is characterized by progressive cognitive decline, severe brain atrophy and neuroinflammation. We conducted a randomized, double-blind, placebo-controlled, parallel-group phase 2a clinical trial that tested the safety and efficacy of laromestrocel, a bone-marrow-der...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Ingarihi |
| I whakaputaina: |
2025
|
| Urunga tuihono: | https://doi.org/10.1038/s41591-025-03559-0 |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Me noho koe te mea tuatahi ki te waiho tākupu!